Cosmo (COPN) Pharma’s Stock Skyrockets on Hair-Loss Cure скачать в хорошем качестве

Cosmo (COPN) Pharma’s Stock Skyrockets on Hair-Loss Cure

This week, Cosmo Pharmaceuticals (SIX: COPN) shocked the biotech market after releasing Phase 3 trial results for a new topical hair-loss treatment that delivered up to 5× more regrowth than placebo — without the hormonal side-effects associated with finasteride. The stock instantly surged over 40%… but the bigger story goes far beyond the headline move. In this video, we break down: 🧬 The science behind Cosmo’s clascoterone hair-loss drug (a new local DHT blocker) ✅ Phase 3 results — why +539% hair growth matters and how it compares to finasteride & minoxidil 📈 The stock reaction & valuation — $1.5B market cap, profitable biotech with dividend 🎯 The addressable market — a potential $20B+ US opportunity 📊 TradingView chart technicals — support, resistance & breakout levels 🧠 Investor profile — who this stock is for and where the risks still lie Cosmo isn’t a typical early-stage biotech — it already runs profitable dermatology and GI franchises, including Winlevi (the #1 topical acne drug in the US) and an AI-powered colonoscopy diagnostics partnership with Medtronic. With regulatory filings expected in 2026 and commercialization potentially shortly thereafter, Cosmo may be riding its biggest product cycle yet. ⚠️ Disclaimer This video is for educational purposes only — not financial advice. Always conduct your own research before making investment decisions. 👍 If you enjoyed this analysis… Please like, subscribe, and comment — especially if you’re following biotech, healthcare stocks, or emerging consumer health trends. It’s a controversial space and I’d love to hear your take. #CosmoPharma #BiotechStocks #HairLossTreatment #StockMarketAnalysis #HealthcareInvesting #GrowthStocks #Dermatology #Phase3Trials #FinasterideAlternative #Investing